🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

8 results for “nilotinib” Clear

  1. DASATINIB, IMATINIB, BOSUTINIB, DASATINIB, NILOTINIB, BOSUTINIB, DASATINIB, DASATINIB, NILOTINIB, DASATINIB, IMATINIB, IMATINIB, DASATINIB, ASCIMINIB HYDROCHLORIDE

    Novartis Ophthalmics Europe

    Chronic Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  2. NILOTINIB, ASCIMINIB HYDROCHLORIDE, NILOTINIB, NILOTINIB

    Novartis Ophthalmics Europe

    Chronic Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  3. Nilotinib

    China SXT Pharmaceuticals

    Chronic Myeloid Leukemia, Chronic Phase

    phase 3 small molecule active

    1 trial

  4. Tasigna 200 mg hard capsules, DASATINIB, IMATINIB, DASATINIB, ASCIMINIB HYDROCHLORIDE, NILOTINIB, IMATINIB, DASATINIB, NILOTINIB, BOSUTINIB, BOSUTINIB, Tasigna 150 mg hard capsules, DASATINIB, Tasigna 150 mg hard capsules, Tasigna 150 mg hard capsules, IMATINIB, Tasigna 150 mg hard capsules, Tasigna 200 mg hard capsules, Tasigna 200 mg hard capsules, Tasigna 200 mg hard capsules, Tasigna 150 mg hard capsules, Tasigna 200 mg hard capsules, ASCIMINIB HYDROCHLORIDE, Tasigna 200 mg hard capsules

    Novartis Ophthalmics Europe

    chronic myelogenous leukemia (CML) or Philadelphia Chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

    phase 3 small molecule active

    1 trial

  5. Scemblix 40 mg film-coated tablets, Scemblix 40 mg film-coated tablets, Scemblix 20 mg film-coated tablets, Scemblix 40 mg film-coated tablets, NILOTINIB, NILOTINIB, Scemblix 20 mg film-coated tablets, IMATINIB, IMATINIB

    Novartis Ophthalmics Europe

    Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with imatinib and have not achieved deep molecular response

    phase 2 small molecule active

    1 trial

  6. nilotinib

    United Therapeutics Europe Ltd

    Mucosal Lentiginous Melanoma

    phase 2 small molecule completed

    1 trial

  7. Bioequivalence of Nilotinib 200 mg Capsules in Healthy Participants Under Fasting Conditions.

    Pharma Mar S.A.

    No medical condition.

    phase 1 other active

    1 trial

  8. IMATINIB , PONATINIB , BOSUTINIB, NILOTINIB, DASATINIB

    Disc Medicine

    Chronic myeloid leukaemia

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources